"Оземпик" и Ко: как препараты действуют на сердце, мозг и печень

Когда речь заходит про «Оземпик» и препараты со сходным действием, первая реакция большинства:

Если копнуть глубже, окажется, что лекарства работают не только как «шоковый удар по аппетиту». У них много приятных «бонусов», которые незаслуженно обделяют вниманием. О них и поговорим в карточках

Мы с командой долго работали над исчерпывающим Гайдом по препаратам для похудения.

Если хочешь досконально разобраться и получить исчерпывающую и проверенную информацию по теме — переходи по ссылке.

Дисклеймер: проект не осуществляет назначение препаратов, корректировку дозировок и иные виды медицинской деятельности. Информация не является рекомендацией или призывом к действию. Перед применением необходимо проконсультироваться с врачом.

Список источников:

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding, 2021)
2. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (Louis J. Aronne 2025)
3. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials (Dario Giugliano, 2019)
4. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
(Mikhail N. Kosiborod, 2023)
5. Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials (Hiddo J.L. Heerspink, 2023)
6. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease (Kai Zhu 2023)
7. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ (US Food and Drug Administration 2025)
8. Mapping the effectiveness and risks of GLP-1 receptor agonists (Yan Xie, 2025)
9. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population (William Wang, 2024)
10. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I (1992)
11. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II (JAMA, 1997)
12. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE) (Whelton, 1998)
13. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial (Appel, 2003)
14. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial (Look AHEAD Research Group, 2010)
15. Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding, 2021)
16. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial (Rubino, 2021)
17. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (Garvey, 2022)
18. Semaglutide and blood pressure: an individual patient data meta-analysis (Kennedy, 2024)
19. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis (Wu, 2023)
20. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis (Vilar-Gomez, 2015)
21. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial (Wong, 2013)
22. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis (Newsome, 2021)
23. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (Sanyal, 2025)
24. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (Loomba, 2024)
25. Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: Post Hoc Analysis of the SUSTAIN and PIONEER Programs (Cherney, 2022)
26. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial (Look AHEAD Research Group, 2010)
27. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes (Look AHEAD Research Group, 2011)
28. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes (Gummesson et al., 2017)
29. Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli (Carol Cheney, 2025)